Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203836 | 0.87 | RAB9A (0.60) | MAOBMAOAMAPTLMNAKMT2A | |
| SCHEMBL18069820 | 0.86 | MAOB (0.58) | MAOBMAOAMAPTLMNAKMT2A | |
| SCHEMBL11632216 | 0.86 | RAB9A (0.62) | MAOBMAOAMAPTLMNAKMT2A | |
| SCHEMBL1130104 | 0.85 | MAOB (0.57) | MAOBMAOAMAPTLMNAKMT2A | |
| SCHEMBL31081305 | 0.85 | RAB9A (0.62) | MAOBMAOAMAPTLMNAKMT2A | |
| SCHEMBL4688326 | 0.85 | MAOB (0.53) | MAOBMAOAMAPTLMNAKMT2A | |
| SCHEMBL28145792 | 0.85 | RAB9A (0.62) | MAOBMAOAMAPTLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL11632213 | 0.84 | RAB9A (0.61) | MAOBMAOAMAPTLMNAKMT2A | |
| SCHEMBL3276281 | 0.84 | RAB9A (0.57) | MAOBMAOAMAPTLMNAKMT2A | |
| SCHEMBL1493670 | 0.84 | KMT2A (0.60) | MAOBMAOAMAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001390-A | Boronic acid derivatives | 默克专利股份公司 | 2017-08-01 | — | — | CN | disclosed |
| US-20170210744-A1 | PROCESS FOR PREPARING A CARBAPENEM ANTIBIOTIC | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-07-27 | — | — | US | disclosed |
| CN-106478700-A | The phenyl aminess kinases inhibitor that boryl replaces | 杭州雷索药业有限公司 | 2017-03-08 | — | — | CN | disclosed |
| WO-2015145161-A1 | PROCESS FOR PREPARING A CARBAPENEM ANTIBIOTIC | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2015-10-01 | — | — | WO | disclosed |
| WO-2013051672-A1 | MEDICINAL AGENT COMPRISING THIAZOLIDINE DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | 株式会社ヤクルト本社 (JP) | 2013-04-11 | — | — | WO | disclosed |
| WO-2010120994-A2 | UREIDOARYL-AND CARBAMOYLARYL-MORPHOLINO- PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2004106291-A1 | HALOETHYL UREA COMPOUNDS AND THE USE THEREOF TO ATTENUATE, INHIBIT OR PREVENT CANCER CELL MIGRATION | IMOTEP INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004106292-A1 | HALOETHYL UREA COMPOUNDS AND THEIR USE TO ATTENUATE, INHIBIT OR PREVENT NON-CANCEROUS PATHOGENIC CELLULAR PROLIFERATION AND DISEASES ASSOCIATED THEREWITH | IMOTEP INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| CN-1151140-C | Glucokinase activators | - | 2004-05-26 | — | — | CN | disclosed |
| CN-1349519-A | Glucokinase activators | HOFFMANN LA ROCHE (CH) | 2002-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210744-A1 | PROCESS FOR PREPARING A CARBAPENEM ANTIBIOTIC | MGAM, HAMP, MB | MAOB 2362/4885MAOA 1606/4885MAPT 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.